Chordate Medical Holding AB (publ) (CMH.ST)
SEK 12.6
(-1.18%)
SEK 12.6
(-1.18%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.86 Million SEK | -9.24% |
| 2022 | 7.56 Million SEK | 48.07% |
| 2021 | 5.11 Million SEK | -8.33% |
| 2020 | 5.57 Million SEK | -29.17% |
| 2019 | 7.87 Million SEK | -20.14% |
| 2018 | 9.85 Million SEK | -9.68% |
| 2017 | 10.91 Million SEK | -5.73% |
| 2016 | 11.57 Million SEK | -2.6% |
| 2015 | 11.88 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 6.73 Million SEK | -1.9% |
| 2024 Q2 | 6 Million SEK | -10.93% |
| 2023 Q1 | 5.56 Million SEK | -26.43% |
| 2023 Q2 | 5.29 Million SEK | -4.83% |
| 2023 Q3 | 4.31 Million SEK | -18.63% |
| 2023 FY | 6.86 Million SEK | -9.24% |
| 2023 Q4 | 6.86 Million SEK | 59.31% |
| 2022 Q3 | 4.21 Million SEK | -6.85% |
| 2022 FY | 7.56 Million SEK | 48.07% |
| 2022 Q1 | 4.72 Million SEK | -7.47% |
| 2022 Q2 | 4.52 Million SEK | -4.39% |
| 2022 Q4 | 7.56 Million SEK | 79.67% |
| 2021 FY | 5.11 Million SEK | -8.33% |
| 2021 Q4 | 5.11 Million SEK | -52.77% |
| 2021 Q3 | 10.82 Million SEK | 148.78% |
| 2021 Q2 | 4.34 Million SEK | -8.83% |
| 2021 Q1 | 4.77 Million SEK | -14.43% |
| 2020 Q2 | 7.28 Million SEK | 14.56% |
| 2020 FY | 5.57 Million SEK | -29.17% |
| 2020 Q3 | 4 Million SEK | -45.04% |
| 2020 Q4 | 5.57 Million SEK | 39.32% |
| 2020 Q1 | 6.35 Million SEK | -19.25% |
| 2019 Q4 | 7.87 Million SEK | -1.21% |
| 2019 Q1 | 8.7 Million SEK | -11.73% |
| 2019 FY | 7.87 Million SEK | -20.14% |
| 2019 Q2 | 10.83 Million SEK | 24.53% |
| 2019 Q3 | 7.96 Million SEK | -26.45% |
| 2018 Q1 | 15.65 Million SEK | 43.42% |
| 2018 FY | 9.85 Million SEK | -9.68% |
| 2018 Q4 | 9.85 Million SEK | 42.87% |
| 2018 Q3 | 6.89 Million SEK | -39.27% |
| 2018 Q2 | 11.36 Million SEK | -27.42% |
| 2017 Q2 | 4.98 Million SEK | -5.2% |
| 2017 FY | 10.91 Million SEK | -5.73% |
| 2017 Q3 | 5.13 Million SEK | 2.98% |
| 2017 Q1 | 5.25 Million SEK | -54.59% |
| 2017 Q4 | 10.91 Million SEK | 112.61% |
| 2016 FY | 11.57 Million SEK | -2.6% |
| 2016 Q4 | 11.57 Million SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | 11.88 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | 37.544% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.743% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.743% |
| Arcoma AB | 33.3 Million SEK | 79.376% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 97.917% |
| BICO Group AB (publ) | 3.26 Billion SEK | 99.79% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 97.546% |
| CellaVision AB (publ) | 212.32 Million SEK | 96.765% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | 51.617% |
| C-Rad AB (publ) | 122.4 Million SEK | 94.388% |
| Duearity AB (publ) | 17.53 Million SEK | 60.816% |
| Dignitana AB (publ) | 37.56 Million SEK | 81.715% |
| Episurf Medical AB (publ) | 19.8 Million SEK | 65.308% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.972% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | 66.656% |
| Iconovo AB (publ) | 14.55 Million SEK | 52.803% |
| Integrum AB (publ) | 22.07 Million SEK | 68.881% |
| Luxbright AB (publ) | 7 Million SEK | 1.874% |
| Mentice AB (publ) | 163.55 Million SEK | 95.8% |
| OssDsign AB (publ) | 105.25 Million SEK | 93.474% |
| Paxman AB (publ) | 44.5 Million SEK | 84.567% |
| Promimic AB (publ) | 16.15 Million SEK | 57.484% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 88.951% |
| SciBase Holding AB (publ) | 21.27 Million SEK | 67.718% |
| ScandiDos AB (publ) | 37.18 Million SEK | 81.528% |
| Sectra AB (publ) | 1.64 Billion SEK | 99.582% |
| Sedana Medical AB (publ) | 44.06 Million SEK | 84.411% |
| Senzime AB (publ) | 58.06 Million SEK | 88.17% |
| SpectraCure AB (publ) | 14.97 Million SEK | 54.131% |
| Stille AB | 172.64 Million SEK | 96.021% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 99.813% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 97.259% |